Aquestive Therapeutics is a specialty pharmaceutical company dedicated to improving patient lives through innovative drug delivery technologies. The company focuses on developing orally administered products that offer alternatives to traditional therapies, utilizing its proprietary PharmFilm® technology to effectively deliver complex molecules.
Transitioning from licensing its technology to developing its own products, Aquestive has a strong presence in the central nervous system (CNS) and allergy therapeutic areas. It has four commercialized products marketed globally by licensees, for which it serves as the exclusive manufacturer. Key products include Anaphylm™, a sublingual epinephrine film for treating severe allergic reactions, and Libervant™, a proprietary product targeting epilepsy. The company also explores earlier-stage candidates, such as an epinephrine prodrug topical gel for dermatological conditions.
With a business model that combines product development, licensing, and manufacturing partnerships, Aquestive reported revenues of $37 million for the first nine months of 2024. The company fosters a collaborative culture and is supported by an advisory board of leading physicians, all focused on enhancing patient experiences in complex treatment areas.
Aquestive Therapeutics is a specialty pharmaceutical company dedicated to improving patient lives through innovative drug delivery technologies. The company focuses on developing orally administered products that offer alternatives to traditional therapies, utilizing its proprietary PharmFilm® technology to effectively deliver complex molecules.
Transitioning from licensing its technology to developing its own products, Aquestive has a strong presence in the central nervous system (CNS) and allergy therapeutic areas. It has four commercialized products marketed globally by licensees, for which it serves as the exclusive manufacturer. Key products include Anaphylm™, a sublingual epinephrine film for treating severe allergic reactions, and Libervant™, a proprietary product targeting epilepsy. The company also explores earlier-stage candidates, such as an epinephrine prodrug topical gel for dermatological conditions.
With a business model that combines product development, licensing, and manufacturing partnerships, Aquestive reported revenues of $37 million for the first nine months of 2024. The company fosters a collaborative culture and is supported by an advisory board of leading physicians, all focused on enhancing patient experiences in complex treatment areas.
Est Monthly Spend
Repeat Buy Rate
Direct Response
Est. Spend
Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.
